illumina immunochip microarray (Illumina Inc)
Illumina Inc is a verified supplier 
90
Structured Review
Illumina Inc
illumina immunochip microarray
Illumina Immunochip Microarray, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+immunochip/illumina+immunochip/pmc11172491-183-26-26
Average 90 stars, based on 1 article reviews
Illumina Immunochip Microarray, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+immunochip/illumina+immunochip/pmc11172491-183-26-26
Average 90 stars, based on 1 article reviews
illumina immunochip microarray - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
GWAS:Article Title: A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches. Article Snippet: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS); it develops with progressive neurodegeneration mainly due to autoimmune inflammation (Nylander and Hafler 2012).. MS is diagnosed in about 2.3 million people worldwide (Browne et al. 2014), affects mostly young people leading to early disability, and reduces the lifespan by approximately 7 years as compared with the general population (Marrie et al. 2015; Kaufman et al. 2014; Leray et al. 2015).. MS is a complex disease: several causes underlie its development and are still incompletely understood (Marian 2012; Kilpinen and Barrett 2013). Microarray:Article Title: A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches. Article Snippet: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS); it develops with progressive neurodegeneration mainly due to autoimmune inflammation (Nylander and Hafler 2012).. MS is diagnosed in about 2.3 million people worldwide (Browne et al. 2014), affects mostly young people leading to early disability, and reduces the lifespan by approximately 7 years as compared with the general population (Marrie et al. 2015; Kaufman et al. 2014; Leray et al. 2015).. MS is a complex disease: several causes underlie its development and are still incompletely understood (Marian 2012; Kilpinen and Barrett 2013). |